 Connection
Martin McCarter to Adenocarcinoma
This is a "connection" page, showing publications Martin McCarter has written about Adenocarcinoma.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.519 |
|
|
|
-
Ho F, Torphy RJ, Friedman C, Leong S, Kim S, Wani S, Schefter T, Scott CD, Mitchell JD, Weyant MJ, Meguid RA, Gleisner AL, Goodman KA, McCarter MD. Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. Ann Surg Oncol. 2021 Nov; 28(12):7208-7218.
Score: 0.447
-
Torphy RJ, Ho F, McCarter MD. ASO Author Reflections: Revisiting the Role of Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. Ann Surg Oncol. 2021 10; 28(11):6058-6059.
Score: 0.447
-
Chapman BC, Gleisner A, Rigg D, Meguid C, Goodman K, Brauer B, Gajdos C, Schulick RD, Edil BH, McCarter MD. Perioperative outcomes and survival following neoadjuvant stereotactic body radiation therapy (SBRT) versus intensity-modulated radiation therapy (IMRT) in pancreatic adenocarcinoma. J Surg Oncol. 2018 Apr; 117(5):1073-1083.
Score: 0.359
-
Paniccia A, Edil BH, Schulick RD, Byers JT, Meguid C, Gajdos C, McCarter MD. Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study. Medicine (Baltimore). 2014 Dec; 93(27):e198.
Score: 0.287
-
Stuart CM, Dyas AR, Yee EJ, Thielen O, Bronsert MR, Mungo B, McCarter MD, Randhawa SK, David EA, Michell JD, Meguid RA. Patient, facility, and surgical factors associated with significant delays to esophagectomy and subsequent poor outcomes: An analysis of 16,486 cases. J Thorac Cardiovasc Surg. 2025 May; 169(5):1385-1395.e5.
Score: 0.143
-
Yee EJ, Read J, Ziogas IA, Stuart CM, Olsen J, Kim SS, Mitchell JD, Meguid RA, McCarter MD, Mungo B. More May Not Be Better: Comparison of Oncologic Outcomes Following Induction Chemotherapy Plus Chemoradiation and Chemoradiation Alone for Esophageal Adenocarcinoma. J Surg Oncol. 2025 Mar; 131(4):598-606.
Score: 0.143
-
Ziogas IA, Thielen ON, Ghaffar SA, Yee EJ, Khomiak A, Durden JA, Kim S, Schulick RD, Gleisner AL, McCarter MD, Mungo B. The Role of Metastasectomy in Patients with Liver-Only Metastases from Gastric Adenocarcinoma. Ann Surg Oncol. 2025 Jan; 32(1):391-398.
Score: 0.142
-
Khomiak A, Ghaffar S, Rodriguez Franco S, Ziogas IA, Yee EJ, Franklin O, Cumbler E, Chauhan A, McCarter MD, Gleisner AL, Ahrendt S, Del Chiaro M, Schulick RD, Mungo B. Survival Outcomes of Cytoreductive Surgery with HIPEC in Gastric Adenocarcinoma: A National Cancer Database Study. Ann Surg Oncol. 2024 Dec; 31(13):8549-8559.
Score: 0.141
-
Schulick AC, Moore HB, Franco SR, Jiang JG, Edil BH, Schulick RD, Nydam TL, McCarter MD, Del Chiaro M, Gleisner A. Gaining a new angle on pancreas cancer: A pre-operative thrombelastographic parameter predicts recurrence and survival among patients with resected periampullary and pancreatic adenocarcinoma. Am J Surg. 2024 Dec; 238:115820.
Score: 0.140
-
Lai SH, Vogel JD, Vemuru S, Messersmith W, Lieu C, McCarter MD, Birnbaum E, Chapman BC. Improved Survival After Adjuvant Therapy in Locally Advanced Rectal Cancer Patients With Pathologic Complete Response. Dis Colon Rectum. 2023 07 01; 66(7):983-993.
Score: 0.126
-
Han S, Kolb JM, Hosokawa P, Friedman C, Fox C, Scott FI, Lieu CH, Vajravelu RK, McCarter M, Murphy CC, Cook MB, Gleisner A, Falk GW, Katzka DA, Wani S. The Volume-Outcome Effect Calls for Centralization of Care in Esophageal Adenocarcinoma: Results From a Large National Cancer Registry. Am J Gastroenterol. 2021 04; 116(4):811-815.
Score: 0.111
-
Halpern AL, Kohtz PD, White AM, Houk AK, Rehring JF, Hanson L, McCarter MD, Joshi M, Meng X, Fullerton DA, Weyant MJ. Secretory Phospholipase A2 IIa Mediates Expression of Growth Factor Receptors in Esophageal Adenocarcinoma. Dig Dis Sci. 2021 03; 66(3):784-795.
Score: 0.104
-
Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. J Natl Cancer Inst. 2019 08 01; 111(8):782-794.
Score: 0.099
-
Moore HB, Paniccia A, Lawson PJ, Torphy RJ, Nydam TL, Moore EE, McCarter MD, Schulick RD, Edil BH. Utility of Viscoelastic Assays Beyond Coagulation: Can Preoperative Thrombelastography Indices Predict Tumor Histology, Nodal Disease, and Resectability in Patients Undergoing Pancreatectomy? J Am Coll Surg. 2018 07; 227(1):55-62.
Score: 0.090
-
Chapman BC, Gajdos C, Hosokawa P, Henderson W, Paniccia A, Overbey DM, Gleisner A, Schulick RD, McCarter MD, Edil BH. Comparison of laparoscopic to open pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Surg Endosc. 2018 05; 32(5):2239-2248.
Score: 0.088
-
Norton JA, Kim T, Kim J, McCarter MD, Kelly KJ, Wong J, Sicklick JK. SSAT State-of-the-Art Conference: Current Surgical Management of Gastric Tumors. J Gastrointest Surg. 2018 01; 22(1):32-42.
Score: 0.087
-
Chapman BC, Gleisner A, Ibrahim-Zada I, Overbey DM, Paniccia A, Meguid C, Brauer B, Gajdos C, McCarter MD, Schulick RD, Edil BH. Laparoscopic pancreaticoduodenectomy: changing the management of ampullary neoplasms. Surg Endosc. 2018 Feb; 32(2):915-922.
Score: 0.086
-
Hintzsche J, Kim J, Yadav V, Amato C, Robinson SE, Seelenfreund E, Shellman Y, Wisell J, Applegate A, McCarter M, Box N, Tentler J, De S, Robinson WA, Tan AC. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples. J Am Med Inform Assoc. 2016 07; 23(4):721-30.
Score: 0.079
-
Merkow RP, Bilimoria KY, McCarter MD, Chow WB, Gordon HS, Stewart AK, Ko CY, Bentrem DJ. Effect of histologic subtype on treatment and outcomes for esophageal cancer in the United States. Cancer. 2012 Jul 01; 118(13):3268-76.
Score: 0.058
-
Gerich ME, McManus MC, McCarter M, Fukami N. Multifocal pouch body adenocarcinoma following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis. Inflamm Bowel Dis. 2011 Aug; 17(8):E96-8.
Score: 0.056
-
Dasari A, McCarter M, McManus MC, Russ P, Messersmith WA. Recurrent pancreatic adenocarcinoma after pancreatic resection. Oncology (Williston Park). 2010 Dec; 24(14):1329-34.
Score: 0.054
-
Koyanagi K, Bilchik AJ, Saha S, Turner RR, Wiese D, McCarter M, Shen P, Deacon L, Elashoff D, Hoon DS. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clin Cancer Res. 2008 Nov 15; 14(22):7391-6.
Score: 0.047
-
Ballonoff A, Kavanagh B, McCarter M, Kane M, Pearlman N, Nash R, Shah RJ, Raben D, Schefter TE. Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. Am J Clin Oncol. 2008 Jun; 31(3):264-70.
Score: 0.046
-
Schefter TE, Patel M, McCarter M, Kane M, Russ PD, Nash SR, Shah RJ, Mitchell JD. Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, Part 2. Oncology (Williston Park). 2005 Jun; 19(7):830, 835-6, 838 passim.
Score: 0.037
-
Schefter TE, Patel M, McCarter M, Kane M, Russ PD, Nash SR, Shah RJ, Mitchell JD. Triple-modality therapy for a woman with locally advanced thoracic esophageal adenocarcinoma, part 1. Oncology (Williston Park). 2005 May; 19(6):775-8, 783-4, 788 passim.
Score: 0.037
-
Chapman BC, Lai SH, Friedrich T, Lieu CH, Moskalenko M, Olsen JR, Herter W, Birnbaum EH, McCarter MD, Vogel JD. Rectal Cancer: Clinical and Molecular Predictors of a Complete Response to Total Neoadjuvant Therapy. Dis Colon Rectum. 2023 04 01; 66(4):521-530.
Score: 0.029
-
Rivadeneira DE, Naama HA, McCarter MD, Fujita J, Evoy D, Mackrell P, Daly JM. Glucocorticoid blockade does not abrogate tumor-induced cachexia. Nutr Cancer. 1999; 35(2):202-6.
Score: 0.024
-
Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D. Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to therapy. Am J Clin Oncol. 2009 Apr; 32(2):115-21.
Score: 0.012
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|